Зофеноприл: осталось ли место для еще одного ингибитора АПФ?


Е.Н. Данковцева, Д.А. Затейщиков

Рассматриваются фармакологические и клинические особенности зофеноприла – ингибитора АПФ, недавно появившегося на российском лекарственном рынке. Зофеноприл – это пролекарство, которое быстро всасывается и почти полностью конвертируется в активный метаболит, зофеноприлат, путем деэтерификации. Препарат характеризуется высокой липофильностью и способен взаимодействовать с тканевым АПФ. В рандомизированных клинических исследованиях подтверждена высокая эффективность зофеноприла при лечении артериальной гипертензии, острого инфаркта миокарда. Обсуждаются особые свойства зофеноприла, отличающие его от других ингибиторов АПФ, в частности его антиоксидантная активность и влияние на атерогенез. Эти особые характеристики находят отражение в кардиопротективной активности препарата, которая выше, чем у многих других ингибиторов АПФ.

Литература






  1. Subissi A, Evangelista S, Giachetti A. Preclinical profile of zofenopril: an angiotensin converting enzyme inhibitor with peculiar cardioprotective properties. Cardiovascular Drug Review 1999; 17(2):115–33.


  2. DeForrest JM, Waldron TL, Krapcho J, et al. Preclinical pharmacology of zofenopril, an inhibitor of angiotensin I converting enzyme. J Cardiovasc Prarmacol 1989;13(6):887–94.


  3. Cushman DW, Wang FL, Fung WS, et al. Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE). Br J Clin Pharmacol 1989;28(115):S131.


  4. Sun Y, Mendelsohn FA. Angiotensin converting enzyme inhibition in heart, kidney, and serum studied ex vivo after adminidtration of zofenopril, captopril, and lisinopril. J Cardiovasc Prarmacol 1991;18(4):478–86.


  5. Marzo A, Dal Bo L, Mazzucchelli P, et al. Pharmacokinetics and pharmacodinamics of zofenopril in healthy volunteers. Arzeimittelforschung 1999; 49:992–96.


  6. Singhvi SM, Foley JE, Wilard DA, et al. Disposition of zofenopril calcium in healthy subjects. J Pharm Sci 1990;79:970–73.


  7. Malacco E, Gastiglioni G, Corradi L, et al. Dose-response relationship of zofenopril in essential hypertension. Clin Drug Invest 2002;22(1):9–15.


  8. Lacourciere Y, Provencher P. Comparative effects of zofenopril and hydrochlorothiazide on office and ambulatory blood pressures in mild to moderate essential hypertension. Br J Clin Pharmacol 1989;27(3):371–76.


  9. Borghi C, Bacchelli S, Esposti DD, et al. A review of the angiotensin-converting enzyme inhibitor, zofenopril, in the treatment of cardiovascular diseases // Expert Opinion on Pharmacotherapy 2004;5(9):1965–77.


  10. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332: 80–85.


  11. Borghi C, Bacchelli S, Esposti DD, et al. Effects of the Early ACE Inhibition in Diabetic Nonthrombolyzed Patients With Anterior Acute Myocardial Infarction. Diabetes Care 2003;26:1862–68.


  12. Borghi C, Ambrosioni E. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. Am Heart J 2003; 145:80–87.


  13. Liu X, Engelman RM, Rousou JA, et al. Attenuation of myocardial reperfusion injury by sulfhydryl-containing angiotensin converting enzyme inhibitors. Cardiovasc Drugs Ther 1992;6(4): 437–43.


  14. Sargent CA, Sleph PG, Dzwonczyk S, et al. Cardioprotection in ischemic rat hearts with the SH-containing angiotensin-converting enzyme inhibitor zofenopril: possible involvement of the ATP-sensitive potassium channel. J Pharmacol Exp Ther 1993;265(2):609–18.


  15. Leva C, Mariscalco G, Ferrarese S, et al. The role of zofenopril in myocardial protection during cardioplegia arrest: an isolated rat heart model. J Card Surg 2006;21(1):44–49.


  16. Cominacini L, Pasini A, Garbin U, et al. Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species. Am J Hypertens 2002;15(10 Pt 1): 891–95.


  17. Buikema H, Monnink SH, Tio RA, et al. Comparison of zofenopril and lisinopril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE-inhibitors in experimental heart failure. Br J Pharmacol 2000;130(8):1999–2007.


  18. Napoli C, Sica V, de Nigris F, et al. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J 2004; 148(1):e5.


  19. Westendorp B, Schoemaker RG, van Gilst WH, et al. Hydrochlorothiazide increases plasma or tissue angiotensin-converting enzyme-inhibitor drug levels in rats with myocardial infarction: Differential effects on lisinopril and zofenopril. Eur J Pharmacol 2005;527(1–3):141–49.





Бионика Медиа